Your browser does not support JavaScript! HEPARIN SODIUM IN DEXTROSE (HEPARIN SODIUM AND DEXTROSE) INJECTION [B. BRAUN MEDICAL INC.]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

HEPARIN SODIUM IN DEXTROSE (heparin sodium and dextrose) injection
[B. Braun Medical Inc.]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL New Drug Application
Drug Label Sections

Do not admix with other drugs.

DESCRIPTION

Heparin Sodium in 5% Dextrose Injection is a sterile, nonpyrogenic solution prepared from heparin sodium (derived from porcine intestinal mucosa and standardized for use as an anticoagulant) and Hydrous Dextrose USP in Water for Injection USP. It is to be administered by intravenous injection. The potency is determined by a biological assay using a USP reference standard based on units of heparin activity per milligram.

Heparin is a heterogenous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans having anticoagulant properties. Although others may be present, the main sugars occurring in heparin are: (1) alpha-L-iduronic acid 2-sulfate, (2) 2-deoxy-2-sulfamino-alpha-D-glucose 6-sulfate, (3) beta-D-glucuronic acid, (4) 2-acetamido-2-deoxy-alpha-D-glucose, and (5) alpha-L-iduronic acid. These sugars are present in decreasing amounts, usually in the order (2) > (1) > (4) > (3) > (5), and are joined by glycosidic linkages, forming polymers of varying sizes. Heparin is strongly acidic because of its content of covalently linked sulfate and carboxylic acid groups. In heparin sodium, the acidic protons of the sulfate units are partially replaced by sodium ions.

(See chart below for quantitative information.)

 Structure of Heparin Sodium (representative subunits): Structure of Hydrous Dextrose USP:
 Chemical Structure Chemical Structure
Composition – Each 100 mL Contains:Concentration of Electrolytes
(mEq/liter)
pHCalculated Osmolarity
mOsmol/liter
SolutionHeparin Sodium USPHydrous Dextrose USPDibasic Sodium Phosphate Heptahydrate
USP
Citric Acid Anhydrous USPSodiumPhosphate
Symbol
Citrate
Sodium Metabisulfite NF (antioxidant) <0.07 g
Water for Injection USP qs
Heparin Sodium 20,000 USP units per 500 mL (40 USP units per mL) in 5% Dextrose Injection 4,000 USP units 5 g 0.41 g 0.093 g 38 30 15 5.6
(4.5–7.0)
 315
Heparin Sodium 25,000 USP units per 500 mL (50 USP units per mL) in 5% Dextrose Injection 5,000 USP units 5 g 0.41 g 0.093 g 38 30 15 5.6
(4.5–7.0)
 315
Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection 10,000 USP units 5 g 0.41 g 0.093 g 38 30 15 5.6
(4.5–7.0)
 315

The formulas of the inactive ingredients are:

IngredientsMolecular FormulaMolecular Weight
Dibasic Sodium Phosphate Heptahydrate USP Na2HPO4•7H2O 268.07
Citric Acid Anhydrous USP CH2(COOH)C(OH)(COOH)CH2COOH 192.12

Not made with natural rubber latex, PVC or DEHP.

The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary.

The closure system has two ports; the one for the administration set has a tamper evident plastic protector. Refer to the Directions for Use of the container.

CLINICAL PHARMACOLOGY

Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Heparin acts at multiple sites in the normal coagulation system. Small amounts of heparin in combination with antithrombin III (heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor.

Bleeding time is usually unaffected by heparin. Clotting time is prolonged by full therapeutic doses of heparin; in most cases it is not measurably affected by low doses of heparin.

Patients over 60 years of age, following similar doses of heparin, may have higher plasma levels of heparin and longer activated partial thromboplastin times (APTTs) compared with patients under 60 years of age.

Peak plasma levels of heparin are achieved 2–4 hours following subcutaneous administration, although there are considerable individual variations. Loglinear plots of heparin plasma concentrations with time for a wide range of dose levels are linear which suggests the absence of zero order processes. Liver and the reticuloendothelial system are the sites of biotransformation. The biphasic elimination curve, a rapidly declining alpha phase (t½ = 10 minutes) and after the age of 40 a slower beta phase, indicates uptake in organs. The absence of a relationship between anticoagulant half-life and concentration half-life may reflect factors such as protein binding of heparin.

Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.

Dextrose provides a source of calories. Dextrose is readily metabolized, may decrease losses of body protein and nitrogen, promotes glycogen deposition and decreases or prevents ketosis if sufficient doses are provided.

INDICATIONS AND USAGE

Heparin Sodium in 5% Dextrose Injection is indicated as a continuous intravenous infusion following an initial intravenous therapeutic dose of heparin sodium.

Heparin Sodium Injection is indicated for anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; for prophylaxis and treatment of pulmonary embolism; in atrial fibrillation with embolization; for treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); for prevention of clotting in arterial and heart surgery; and in prophylaxis and treatment of peripheral arterial embolism.

CONTRAINDICATIONS

Heparin sodium should not be used in patients:

With severe thrombocytopenia;

With a known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) (See ADVERSE REACTIONS, Hypersensitivity);

In whom suitable blood coagulation tests – e.g., the whole blood clotting time, partial thromboplastin time, etc., – cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin);

With an uncontrollable active bleeding state (See WARNINGS), except when this is due to disseminated intravascular coagulation.

Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.

WARNINGS

Heparin is not intended for intramuscular use.

Hypersensitivity

Patients with documented hypersensitivity to heparin should be given the drug only in clearly life-threatening situations. (See ADVERSE REACTIONS, Hypersensitivity.)

Because Heparin Sodium in 5% Dextrose Injection is derived from animal tissue, monitor for signs and symptoms of hypersensitivity when it is used in patients with a history of allergy.

Hemorrhage

Hemorrhage can occur at virtually any site in patients receiving heparin. An unexplained fall in hematocrit, fall in blood pressure, or any other unexplained symptom should lead to serious consideration of a hemorrhagic event.

Heparin sodium should be used with extreme caution in disease states in which there is increased danger of hemorrhage. Some of the conditions in which increased danger of hemorrhage exists are:

Cardiovascular – Subacute bacterial endocarditis. Severe hypertension.

Surgical – During and immediately following (a) spinal tap or spinal anesthesia or (b) major surgery, especially involving the brain, spinal cord, or eye.

Hematologic – Conditions associated with increased bleeding tendencies, such as hemophilia, thrombocytopenia and some vascular purpuras.

Gastrointestinal – Ulcerative lesions and continuous tube drainage of the stomach or small intestine.

Other – Menstruation, liver disease with impaired hemostasis.

Coagulation Testing

When heparin sodium is administered in therapeutic amounts, its dosage should be regulated by frequent blood coagulation tests. If the coagulation test is unduly prolonged or if hemorrhage occurs, heparin should be discontinued promptly (See OVERDOSAGE).

Thrombocytopenia

Thrombocytopenia has been reported to occur in patients receiving heparin with a reported incidence of up to to 30%. Platelet counts should be obtained at baseline and periodically during heparin administration. Mild thrombocytopenia (count greater than 100,000/mm3) may remain stable or reverse even if heparin is continued. However, thrombocytopenia of any degree should be monitored closely. If the count falls below 100,000/mm3 or if recurrent thrombosis develops (SeeHeparin-induced Thrombocytopenia (HIT) With or Without Thrombosis), the heparin product should be discontinued, and, if necessary, an alternative anticoagulant administered.

Heparin-induced Thrombocytopenia (HIT) (With or Without Thrombosis)

HIT is a serious immune-mediated reaction resulting from irreversible aggregation of platelets. HIT may progress to the development of venous and arterial thromboses, a condition referred to as HIT with thrombosis. Thrombotic events may also be the initial presentation for HIT. These serious thromboembolic events include deep vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke, myocardial infarction, thrombus formation on a prosthetic cardiac valve, mesenteric thrombosis, renal arterial thrombosis, skin necrosis, gangrene of the extremities that may lead to amputation, and fatal outcomes.

Once HIT (with or without thrombosis) is diagnosed or strongly suspected, all heparin sodium sources (including heparin flushes) should be discontinued and an alternative anticoagulant used.  Future use of heparin sodium, especially within 3 to 6 months following the diagnosis of HIT (with or without thrombosis), and while patients test positive for HIT antibodies, should be avoided.

Immune-mediated HIT is diagnosed based on clinical findings supplemented by laboratory tests confirming the presence of antibodies to heparin sodium, or platelet activation induced by heparin sodium. A drop in platelet count greater than 50% from baseline is considered indicative of HIT. Platelet counts begin to fall 5 to 10 days after exposure to heparin sodium in heparin sodium-naïve individuals, and reach a threshold by days 7 to 14. In contrast, “rapid onset” HIT can occur very quickly (within 24 hours following heparin sodium initiation), especially in patients with a recent exposure to heparin sodium (i.e. previous 3 months). Thrombosis development shortly after documenting thrombocytopenia is a characteristic finding in almost half of all patients with HIT.

Thrombocytopenia of any degree should be monitored closely. If the platelet count falls below 100,000/mm3 or if recurrent thrombosis develops, the heparin product should be promptly discontinued and alternative anticoagulants considered if patients require continued anticoagulation.

Delayed Onset of HIT (With or Without Thrombosis)

Heparin-induced Thrombocytopenia (with or without thrombosis) can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT (with or without thrombosis).

This product contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentration.

Solutions containing dextrose without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility of agglomeration.

Excessive administration of potassium-free solutions may result in significant hypokalemia.

Because dosages of this drug are titrated to response (See DOSAGE AND ADMINISTRATION), no additives should be made to Heparin Sodium in 5% Dextrose Injection.

PRECAUTIONS

General

  1. Thrombocytopenia, Heparin-induced Thrombocytopenia (HIT) (With or Without Thrombosis) and Delayed Onset of HIT (With or Without Thrombosis): (See WARNINGS .)
  2. Heparin Resistance:
    Increased resistance to heparin is frequently encountered in fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction, cancer and in postsurgical patients.
  3. Increased Risk to Older Patients, Especially Women:
    A higher incidence of bleeding has been reported in patients, particularly women, over 60 years of age.

Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance and electrolyte concentrations during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

Solutions containing dextrose should be used with caution in patients with overt or known subclinical diabetes mellitus, or carbohydrate intolerance for any reason.

Do not use plastic container in series connection.

If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result.

These solutions are intended for intravenous administration using sterile equipment. It is recommended that any unused heparin solution and intravenous administration apparatus be replaced at least once every 24 hours.

Use only if solution is clear and container and seals are intact.

Laboratory Tests

Periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy, regardless of the route of administration (See DOSAGE AND ADMINISTRATION).

Drug Interactions

Oral Anticoagulants

Heparin sodium may prolong the one-stage prothrombin time. Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.

Platelet Inhibitors

Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.

Other Interactions

Digitalis, tetracyclines, nicotine, antihistamines, or IV nitroglycerine may partially counteract the anticoagulant action of heparin sodium. Intravenous nitroglycerin administered to heparinized patients may result in a decrease of the partial thromboplastin time with subsequent rebound effect upon discontinuation of nitroglycerin. Careful monitoring of partial thromboplastin time and adjustment of heparin dosage are recommended during coadministration of heparin and intravenous nitroglycerin.

Drug/Laboratory Tests Interactions

Hyperaminotransferasemia

Significant elevations of aminotransferase AST (SGOT) and ALT (SGPT) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin. Since aminotransferase determinations are important in the differential diagnosis of myocardial infarction, liver disease and pulmonary emboli, rises that might be caused by drugs (like heparin) should be interpreted with caution.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long term studies in animals to evaluate the carcinogenic potential, reproduction studies in animals to determine effects on fertility of males and females, and the studies to determine mutagenic potential have not been conducted with Heparin Sodium in 5% Dextrose Injection.

Pregnancy

Pregnancy Category C

There are no adequate and well-controlled studies on heparin use in pregnant women. In published reports, heparin exposure during pregnancy did not show evidence of an increased risk of adverse maternal or fetal outcomes in humans. Heparin sodium does not cross the placenta, based on human and animal studies. Administration of heparin to pregnant animals at doses higher than the maximum human daily dose based on body weight resulted in increased resorptions. Use heparin sodium during pregnancy only if the potential benefit justifies the potential risk to the fetus.

In a published study conducted in rats and rabbits, pregnant animals received heparin intravenously during organogenesis at a dose of 10,000 USP units/kg/day, approximately 10 times the maximum human daily dose based on body weight. The number of early resorptions increased in both species. There was no evidence of teratogenic effects.

Nursing Mothers

Due to its large molecular weight, heparin is not likely to be excreted in human milk, and any heparin in milk would not be orally absorbed by a nursing infant. Exercise caution when administering Heparin Sodium to a nursing mother.

Pediatric Use

There are no adequate and well controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience (See DOSAGE AND ADMINISTRATION, Pediatric Use).

Geriatric Use

A higher incidence of bleeding has been reported in patients over 60 years of age, especially women (See PRECAUTIONS, General). Clinical studies indicate that lower doses of heparin may be indicated in these patients (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

ADVERSE REACTIONS

Hemorrhage

Hemorrhage is the chief complication that may result from heparin therapy (See WARNINGS). An overly prolonged clotting time or minor bleeding during therapy can usually be controlled by withdrawing the drug (See OVERDOSAGE). It should be appreciated that gastrointestinal or urinary tract bleeding during anticoagulant therapy may indicate the presence of an underlying occult lesion. Bleeding can occur at any site but certain specific hemorrhagic complications may be difficult to detect:

  1. Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred during anticoagulant therapy. Therefore, such treatment should be discontinued in patients who develop signs and symptoms of acute adrenal hemorrhage and insufficiency. Initiation of corrective therapy should not depend on laboratory confirmation of the diagnosis, since any delay in an acute situation may result in the patient's death.
     
  2. Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive age receiving short- or long-term anticoagulant therapy. This complication if unrecognized may be fatal.
     
  3. Retroperitoneal hemorrhage.

Thrombocytopenia, Heparin-induced Thrombocytopenia (HIT) (With or Without Thrombosis) and Delayed Onset of HIT (With or Without Thrombosis)

(See WARNINGS.)

Local Irritation

Local irritation, erythema, mild pain, hematoma or ulceration may follow deep subcutaneous (intrafat) injection of heparin sodium. These complications are much more common after intramuscular use, and such use is not recommended.

Hypersensitivity

Generalized hypersensitivity reactions have been reported, with chills, fever, and urticaria as the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and vomiting, and anaphylactoid reactions, including shock, occurring more rarely. Itching and burning, especially on the plantar site of the feet, may occur. (See WARNINGS.)

Certain episodes of painful, ischemic, and cyanosed limbs have in the past been attributed to allergic vasospastic reactions. Whether these are in fact identical to the thrombocytopenia associated complications remains to be determined.

Miscellaneous

Osteoporosis following long-term administration of high-doses of heparin, cutaneous necrosis after systemic administration, suppression of aldosterone synthesis, delayed transient alopecia, priapism, and rebound hyperlipemia on discontinuation of heparin sodium have also been reported.

Significant elevations of aminotransferase AST (SGOT) and ALT (SGPT) levels have occurred in a high percentage of patients (and healthy subjects) who have received heparin.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

OVERDOSAGE

Symptoms

Bleeding is the chief sign of heparin overdosage. Nosebleeds, blood in urine or tarry stools may be noted as the first sign of bleeding. Easy bruising or petechial formations may precede frank bleeding.

Treatment

Neutralization of heparin effect.

When clinical circumstances (bleeding) require reversal of heparinization, protamine sulfate (1% solution) by slow infusion will neutralize heparin sodium. No more than 50 mg should be administered, very slowly, in any 10 minute period. Each mg of protamine sulfate neutralizes approximately 100 USP Heparin Units. The amount of protamine required decreases over time as heparin is metabolized. Although the metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be assumed to have a half-life of about 1/2 hour after intravenous injection.

Administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions. Because fatal reactions often resembling anaphylaxis have been reported, the drug should be given only when resuscitation techniques and treatment of anaphylactoid shock are readily available.

For additional information the labeling of Protamine Sulfate Injection, USP products should be consulted.

DOSAGE AND ADMINISTRATION

Heparin Sodium in 5% Dextrose Injection is for intravenous use only. Do not use Heparin Sodium in 5% Dextrose Injection as a "catheter lock flush" product.

Heparin Sodium is not effective by oral administration and Heparin Sodium in 5% Dextrose Injection should not be given orally.

This product should not be infused under pressure.

The dosage of heparin sodium should be adjusted according to the patient's coagulation test results. When heparin sodium is administered by continuous intravenous infusion, coagulation tests should be performed approximately every 4 hours during the early stages of therapy. Dosage is considered adequate when the activated partial thromboplastin time (APTT) is 1.5 to 2 times normal or when the whole blood clotting time is elevated approximately 2.5 to 3 times the control value.

Periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended during the entire course of heparin therapy, regardless of the route of administration.

When an oral anticoagulant of the coumarin or similar type is to be begun in patients already receiving heparin sodium, baseline and subsequent tests of prothrombin activity must be determined at a time when heparin activity is too low to affect the prothrombin time. This is about 5 hours after the last IV bolus and 24 hours after the last subcutaneous dose. If continuous IV heparin infusion is used, prothrombin time can usually be measured at any time.

In converting from heparin to an oral anticoagulant, the dose of the oral anticoagulant should be the usual initial amount and thereafter prothrombin time should be determined at the usual intervals. To ensure continuous anticoagulation, it is advisable to continue full heparin therapy for several days after the prothrombin time has reached the therapeutic range. Heparin therapy may then be discontinued without tapering.

Although dosage must be adjusted for the individual patient according to the results of suitable laboratory tests, the following dosage schedules may be used as guidelines:

Method of AdministrationFrequencyRecommended Dose*
*
Based on 150-lb. (68-kg) patient.
  Initial dose 5,000 USP units by IV injection
 Continuous Intravenous infusion Continuous 20,000 – 40,000 USP units/24 hours

Pediatric Use

There are no adequate and well controlled studies on heparin use in pediatric patients. Pediatric dosing recommendations are based on clinical experience. In general, the following dosage schedule may be used as a guideline in pediatric patients:

Initial Dose                  75 to 100 USP units/kg (IV bolus over 10 minutes)

Maintenance Dose      Infants: 25 to 30 USP units/kg/hour; Infants less than 2 months have the highest requirements (average 28 USP units/kg/hour)

                                    Children greater than 1 year of age: 18 to 20 USP units/kg/hour; Older children may require less heparin, similar to weight-adjusted adult dosage

Monitoring                    Adjust heparin to maintain aPTT of 60 to 85 seconds, assuming this reflects an anti-Factor Xa level of 0.35 to 0.70.

Geriatric Use

Patients over 60 years of age may require lower doses of heparin. (See PRECAUTIONS.)

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

Heparin Sodium in 5% Dextrose Injection is supplied sterile and nonpyrogenic in EXCEL® containers packaged 24 per case.

NDCREFSize
 

Heparin Sodium 20,000 USP units per 500 mL (40 USP units per mL) in 5% Dextrose Injection

  0264-9567-10 P5671 500 mL
 

Heparin Sodium 25,000 USP units per 500 mL (50 USP units per mL) in 5% Dextrose Injection

  0264-9577-10 P5771 500 mL
 

Heparin Sodium 25,000 USP units per 250 mL (100 USP units per mL) in 5% Dextrose Injection

  0264-9587-20 P5872 250 mL

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.

Storage in automated dispensing machines: Brief exposure up to 2 weeks to ultraviolet or fluorescent light does not adversely affect the product labeling legibility; prolonged exposure can cause fading of the red label. Rotate stock frequently.

Rx only

Revised: September 2013

EXCEL is a registered trademark of B. Braun Medical Inc.

Directions for Use of EXCEL® Container

Do not admix with other drugs.

Caution: Do not use plastic container in series connection.

To Open

Tear overwrap down at notch and remove solution container. Check for minute leaks by squeezing solution container firmly. If leaks are found, discard solution as sterility may be impaired.

 NOTE:

Before use, perform the following checks:

  Inspect each container. Read the label. Ensure solution is the one ordered and is within the expiration date.
 
  Invert container and carefully inspect the solution in good light for cloudiness, haze, or particulate matter. Any container which is suspect should not be used.
 
  Use only if solution is clear and container and seals are intact.

Preparation for Administration

  1. Remove plastic protector from sterile set port at bottom of container.
  2. Attach administration set. Refer to complete directions accompanying set.

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
1-800-227-2862
www.bbraun.com
Made in USA

Y36-002-847  LD-239-5

PRINCIPAL DISPLAY PANEL - 500 mL Container Label

HEPARIN SODIUM
20,000 USP units per 500 mL (40 USP units per mL)
in 5% Dextrose Injection

NDC 0264-9567-10

500 mL
EXCEL® CONTAINER

20,000 USP units per 500 mL
(40 USP units per mL)
HEPARIN

LD-306-2     Y94-003-161

Each 100 mL contains: Heparin Sodium USP
(porcine intestinal mucosa) 4,000 USP Heparin units
Hydrous Dextrose USP 5 g
Dibasic Sodium Phosphate•7H2O USP 0.41 g
Citric Acid Anhydrous USP 0.093 g
Sodium Metabisulfite NF (antioxidant) <0.07 g
Water for Injection USP qs

Electrolytes (mEq/liter):         Sodium 38
Phosphate (HPO =4) 30           Citrate 15

WARNING: CONTAINS SULFITES. Do not admix with other drugs.

Sterile. Single dose container.

For intravenous use only.

Recommended Storage: Room temperature (25°C). Avoid excessive heat. Protect from freezing. See Package Insert. Do not remove overwrap until ready for use. 

REF P5671
Latex free, DEHP free and PVC free
Rx only
Other

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
Made in USA      

LD-305-2     Y94-003-160

EXP
LOT

P5671 Container Label

PRINCIPAL DISPLAY PANEL - 500 mL Container Label

HEPARIN SODIUM
25,000 USP units per 500 mL
(50 USP units per mL)
in 5% Dextrose Injection

NDC 0264-9577-10

500 mL
EXCEL® CONTAINER

25,000 USP units per 500 mL
(50 USP units per mL)
HEPARIN

LD-308-2     Y94-003-163

Each 100 mL contains: Heparin Sodium USP
(porcine intestinal mucosa) 5,000 USP Heparin units
Hydrous Dextrose USP 5 g
Dibasic Sodium Phosphate•7H2O USP 0.41 g
Citric Acid Anhydrous USP 0.093 g
Sodium Metabisulfite NF (antioxidant) <0.07 g
Water for Injection USP qs

Electrolytes (mEq/liter):    Sodium 38
Phosphate (HPO= 4) 30       Citrate 15

WARNING: CONTAINS SULFITES. Do not admix with other drugs.

Sterile. Single dose container.

For intravenous use only.

Recommended Storage: Room temperature (25°C). Avoid excessive heat. Protect from freezing. See Package Insert. Do not remove overwrap until ready for use.

REF P5771
Latex free, DEHP free and PVC free
Rx only
Other

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
Made in USA   

LD-307-2     Y94-003-162

EXP
LOT

P5771 Container Label

PRINCIPAL DISPLAY PANEL - 250 mL Container Label

HEPARIN SODIUM
25,000 USP units per 250 mL
(100 USP units per mL)
in 5% Dextrose Injection

NDC 0264-9587-20

250 mL
EXCEL® CONTAINER

25,000 USP units per 250 mL
(100 USP units per mL)
HEPARIN

LD-310-2     Y94-003-165

Each 100 mL contains:
Heparin Sodium USP (porcine intestinal mucosa) 10,000 USP Heparin units;
Hydrous Dextrose USP 5 g;
Dibasic Sodium Phosphate•7H2O USP 0.41 g;
Citric Acid Anhydrous USP 0.093 g;
Sodium Metabisulfite NF (antioxidant) <0.07 g
Water for Injection USP qs

Electrolytes (mEq/liter):   Sodium 38
Phosphate (HPO =4) 30;    Citrate 15

WARNING: CONTAINS SULFITES. Do not admix with other drugs.

Sterile. Single dose container.

For intravenous use only.

Recommended Storage: Room temperature (25°C). Avoid excessive heat. Protect from freezing. See Package Insert. Do not remove overwrap until ready for use. 

REF P5872
Latex free, DEHP free and PVC free     
Rx only
Other

B. Braun Medical Inc.
Irvine, CA 92614-5895 USA
Made in USA    

LD-309-2     Y94-003-164

EXP
LOT

P5872 Container Label
HEPARIN SODIUM IN DEXTROSE 
heparin sodium and dextrose injection
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:0264-9567
Route of AdministrationINTRAVENOUSDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
HEPARIN SODIUM (HEPARIN) HEPARIN4000 [USP'U]  in 100 mL
DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE5 g  in 100 mL
Inactive Ingredients
Ingredient NameStrength
WATER 
SODIUM PHOSPHATE, DIBASIC0.41 g  in 100 mL
ANHYDROUS CITRIC ACID0.093 g  in 100 mL
SODIUM METABISULFITE0.07 g  in 100 mL
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0264-9567-1024 in 1 CASE
1500 mL in 1 CONTAINER
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01995207/20/1992
HEPARIN SODIUM IN DEXTROSE 
heparin sodium and dextrose injection
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:0264-9577
Route of AdministrationINTRAVENOUSDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
HEPARIN SODIUM (HEPARIN) HEPARIN5000 [USP'U]  in 100 mL
DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE5 g  in 100 mL
Inactive Ingredients
Ingredient NameStrength
WATER 
SODIUM PHOSPHATE, DIBASIC0.41 g  in 100 mL
ANHYDROUS CITRIC ACID0.093 g  in 100 mL
SODIUM METABISULFITE0.07 g  in 100 mL
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0264-9577-1024 in 1 CASE
1500 mL in 1 CONTAINER
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01995207/20/1992
HEPARIN SODIUM IN DEXTROSE 
heparin sodium and dextrose injection
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:0264-9587
Route of AdministrationINTRAVENOUSDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
HEPARIN SODIUM (HEPARIN) HEPARIN10000 [USP'U]  in 100 mL
DEXTROSE MONOHYDRATE (ANHYDROUS DEXTROSE) DEXTROSE MONOHYDRATE5 g  in 100 mL
Inactive Ingredients
Ingredient NameStrength
WATER 
SODIUM PHOSPHATE, DIBASIC0.41 g  in 100 mL
ANHYDROUS CITRIC ACID0.093 g  in 100 mL
SODIUM METABISULFITE0.07 g  in 100 mL
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0264-9587-2024 in 1 CASE
1250 mL in 1 CONTAINER
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01995207/20/1992
Labeler - B. Braun Medical Inc. (002397347)

Revised: 9/2013
 
B. Braun Medical Inc.

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services